Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 2
2012 2
2013 3
2014 1
2015 1
2016 1
2017 1
2018 2
2019 1
2020 2
2021 4
2023 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

20 results

Results by year

Citations

1 article found by citation matching

Search results

Filters applied: . Clear all
Page 1
Visual performance in patients with neovascular age-related macular degeneration undergoing treatment with intravitreal ranibizumab.
Sabour-Pickett S, Loughman J, Nolan JM, Stack J, Pesudovs K, Meagher KA, Beatty S. Sabour-Pickett S, et al. J Ophthalmol. 2013;2013:268438. doi: 10.1155/2013/268438. Epub 2013 Feb 21. J Ophthalmol. 2013. PMID: 23533703 Free PMC article.
Purpose. To assess visual function and its response to serial intravitreal ranibizumab (Lucentis, Genentech) in patients with neovascular age-related macular degeneration (nv-AMD). ...Conclusion. Eyes with nv-AMD u
Purpose. To assess visual function and its response to serial intravitreal ranibizumab (Lucentis, Genentech) in pati
Predicting Incremental and Future Visual Change in Neovascular Age-Related Macular Degeneration Using Deep Learning.
Fu DJ, Faes L, Wagner SK, Moraes G, Chopra R, Patel PJ, Balaskas K, Keenan TDL, Bachmann LM, Keane PA. Fu DJ, et al. Ophthalmol Retina. 2021 Nov;5(11):1074-1084. doi: 10.1016/j.oret.2021.01.009. Epub 2021 Jan 28. Ophthalmol Retina. 2021. PMID: 33516917
PURPOSE: To evaluate the predictive usefulness of quantitative imaging biomarkers, acquired automatically from OCT scans, of cross-sectional and future visual outcomes of patients with neovascular age-related macular degeneration ( …
PURPOSE: To evaluate the predictive usefulness of quantitative imaging biomarkers, acquired automatically from OCT scans, of cross-sectional …
Driving vision in patients with neovascular AMD in anti-VEGF treatment.
Ferløv Baselius NJ, Brynskov T, Falk MK, Sørensen TL, Subhi Y. Ferløv Baselius NJ, et al. Acta Ophthalmol. 2021 Dec;99(8):e1360-e1365. doi: 10.1111/aos.14831. Epub 2021 Mar 5. Acta Ophthalmol. 2021. PMID: 33666364 Free article.
PURPOSE: To report real-world experiences on driving vision in patients with neovascular age-related macular degeneration (AMD) undergoing intravitreal anti-VEGF treatment. METHODS: Retrospective cohort study of tr
PURPOSE: To report real-world experiences on driving vision in patients with neovascular age-related macular
Patients' preferences in treatment for neovascular age-related macular degeneration in clinical routine.
Finger RP, Hoffmann AE, Fenwick EK, Wolf A, Kampik A, Kernt M, Neubauer AS, Hirneiss C. Finger RP, et al. Br J Ophthalmol. 2012 Jul;96(7):997-1002. doi: 10.1136/bjophthalmol-2011-301201. Epub 2012 Apr 25. Br J Ophthalmol. 2012. PMID: 22535331
PURPOSE: To assess the effect of ranibizumab treatment for neovascular age-related macular degeneration (nvAMD) on patients' preferences and vision-related quality of life (VRQoL) in a routine clinical setting. METHOD …
PURPOSE: To assess the effect of ranibizumab treatment for neovascular age-related macular dege
Use of Imaging Modalities in Real Life: Impact on Visual Acuity Outcomes of Ranibizumab Treatment for Neovascular Age-Related Macular Degeneration in Germany.
Wachtlin J, Spital G, Schmitz-Valckenberg S, Liakopoulos S, Vögeler J, Müller B, Ziemssen F, Ocean Study Group. Wachtlin J, et al. J Ophthalmol. 2020 Jul 16;2020:8024258. doi: 10.1155/2020/8024258. eCollection 2020. J Ophthalmol. 2020. PMID: 32724669 Free PMC article.
BACKGROUND: To date, there are limited prospective real-world data on the impact of optical coherence tomography (OCT) diagnostics on treatment outcomes in neovascular age-related macular degeneration (nAMD). ...Best-corrected visual
BACKGROUND: To date, there are limited prospective real-world data on the impact of optical coherence tomography (OCT) diagnostics on tre
SEMIAUTOMATED QUANTITATIVE APPROACH TO CHARACTERIZE TREATMENT RESPONSE IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: A Real-World Study.
Roberts PK, Nesper PL, Gill MK, Fawzi AA. Roberts PK, et al. Retina. 2017 Aug;37(8):1492-1498. doi: 10.1097/IAE.0000000000001400. Retina. 2017. PMID: 27997513 Free PMC article.
PURPOSE: To perform a quantitative study of the vascular microstructure in actively treated choroidal neovascularization by optical coherence tomographic angiography. METHODS: Patients undergoing individualized anti-vascular endothelial growth factor …
PURPOSE: To perform a quantitative study of the vascular microstructure in actively treated choroidal neovascularization by op …
Early multifocal electroretinogram findings during intravitreal ranibizumab treatment for neovascular age-related macular degeneration.
Campa C, Hagan R, Sahni JN, Brown MC, Beare NA, Heimann H, Harding SP. Campa C, et al. Invest Ophthalmol Vis Sci. 2011 Jun 1;52(6):3446-51. doi: 10.1167/iovs.10-6588. Invest Ophthalmol Vis Sci. 2011. PMID: 21357390
PURPOSE: To evaluate changes in the multifocal electroretinogram (mfERG) in patients with neovascular age-related macular degeneration (nAMD) undergoing ranibizumab treatment. ...The mfERG response correlated positive …
PURPOSE: To evaluate changes in the multifocal electroretinogram (mfERG) in patients with neovascular age-related
Vascular endothelial growth factor in patients with exudative age-related macular degeneration treated with ranibizumab.
Muether PS, Hermann MM, Viebahn U, Kirchhof B, Fauser S. Muether PS, et al. Ophthalmology. 2012 Oct;119(10):2082-6. doi: 10.1016/j.ophtha.2012.07.041. Epub 2012 Aug 22. Ophthalmology. 2012. PMID: 22920670
OBJECTIVES: To analyze the temporal correlations of vascular endothelial growth factor (VEGF) suppression, morphologic recurrence of choroidal neovascularization (CNV), and visual acuity loss in eyes with exudative age-related macular degener
OBJECTIVES: To analyze the temporal correlations of vascular endothelial growth factor (VEGF) suppression, morphologic recurrence of choroid …
Anatomical measures as predictors of visual outcomes in ranibizumab-treated eyes with neovascular age-related macular degeneration.
Brown DM, Tuomi L, Shapiro H; Pier Study Group. Brown DM, et al. Retina. 2013 Jan;33(1):23-34. doi: 10.1097/IAE.0b013e318263cedf. Retina. 2013. PMID: 23073338 Clinical Trial.
PURPOSE: To investigate if anatomical characteristics of eyes undergoing ranibizumab therapy were predictive of best-corrected visual acuity (BCVA) outcomes over 2 years. METHODS: Post hoc analyses of patients with age-related m
PURPOSE: To investigate if anatomical characteristics of eyes undergoing ranibizumab therapy were predictive of best-co …
Value of Anti-Vascular Endothelial Growth Factor Gene Therapy for Neovascular Age-Related Macular Degeneration.
Berkowitz ST, Patel S. Berkowitz ST, et al. Ophthalmol Retina. 2021 Apr;5(4):357-364. doi: 10.1016/j.oret.2020.08.005. Epub 2020 Aug 17. Ophthalmol Retina. 2021. PMID: 32818623
PURPOSE: To use discounted cash flow (DCF) analysis to estimate the value creation associated with anti-vascular endothelial growth factor (VEGF) genetic therapy for neovascular age-related macular degeneration (nAMD). DESIGN: Economic an …
PURPOSE: To use discounted cash flow (DCF) analysis to estimate the value creation associated with anti-vascular endothelial growth factor ( …
20 results